IndustryCompany release

NervGen Pharma reports C$80.1M cash at Q3 2026 after May public offering; nine-month net income of C$2.5M

Nervgen Pharma Corp. (NGEN) · Mon 16 Nov 2026

NervGen Pharma, a spinal cord injury-focused biotech listed on Nasdaq, filed unaudited interim financials for the period ended September 30, 2026. Cash rose to C$80.1M from C$22.1M at year-end, mainly from a May 2026 public offering and option and warrant exercises. A C$33.9M unrealized gain on the warrant derivative produced nine-month net income of C$2.5M, even though operating expenses rose to C$30.3M and the company posted a Q3 net loss of C$6.4M.

Company's press release (SEC filing): Nervgen Pharma Corp. ↗

Brief written by VigiEye from the company's press release filed with the SEC. Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →